Measuring treatment response in psoriatic arthritis: comparison between PSoriatic Arthritis Response Criteria and Disease Activity Score-28

Clicks: 25
ID: 331837
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #37 of 143 articles by views in Rheumatology Advances in Practice

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 143 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Objectives Despite current UK guidelines recommending the use of the PSoriatic Arthritis Response Criteria (PsARC) to assess response to advanced targeted therapies in Psoriatic Arthritis (PsA) patients, some clinicians use the Disease Activity Score 28 (DAS-28) primarily developed for Rheumatoid Arthritis. Concordance of the two scores in PsA patients commencing advanced therapies has not previously been explored and is investigated here. Methods Utilising data from the ‘Outcomes of Treatment in Psoriatic Arthritis Study Syndicate’ (OUTPASS – RDN-CPMS 13910) cohort; a UK, multi-centre, observational study, component of PsARC and DAS-28 scores were calculated at baseline (pre-treatment), 3-months (3M) and 6-months (6M), following treatment, where available. DAS-28-basedgood/moderate response were combined and compared with PsARC responder status and agreement tested using the Prevalence-adjusted Bias-adjusted Kappa test. Results Of 413 patients, 78% were classified as responders by PsARC at 3M and 73% at 6M, and 80% by DAS-28 at both 3M & 6M. Of 218 visits, where data was recorded for patients with both PsARC and DAS28, at 3M or 6M, 17.9% were overall discordant. Prevalence-adjusted Bias-adjusted Kappa revealed ‘substantial agreement’ (64.22%) between the two scores. Further analysis between the overall concordant/discordant populations showed significant difference with PsARC Patient’s Global Assessments (PtGA), (P = 0.02). Conclusion PsARC and DAS-28-based response criteria show ‘substantial agreement’, supporting the use of either score in patients commencing advanced therapies. PsARC PtGA was the sole subcomponent significantly different (P < 0.05) between the discordant and concordant groups, highlighting an importance in considering patient-perspectives and psycho-social factors affecting response to treatment.
Reference Key
openalex_W7221011667 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Khadijah Patel, Moshiur Rahman Khasru, Nisha Nair, Maarten P. T. de Wit, Arnon Katz, Charlotte Thompson, Meghna Jani, Hector Chinoy, Anne C Barton, Philippa D. K. Curry, James Bluett
Are you one of these authors? Claim your profile
Journal Rheumatology Advances in Practice
Year 2026
DOI
10.1093/rap/rkag120
URL
https://doi.org/10.1093/rap/rkag120
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.